Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical Industries Limited (IL:TEVA)
:TEVA
TEVA Stock Chart & Stats
9672.00
0.44(0.56%)
At close: 4:00 PM EST
9672.00
0.44(0.56%)
Day’s Range― - ―
52-Week Range4,865.00 - 11,350.00
Previous CloseN/A
Volume1.42M
Average Volume (3M)1.92M
Market Cap
₪121.70B
Enterprise Value53.61B
Total Cash (Recent Filing)₪3.56B
Total Debt (Recent Filing)₪17.39B
Price to Earnings (P/E)25.6
Beta0.60
Next Earnings
May 13, 2026EPS Estimate
170.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)297.30
Shares Outstanding1,164,638,700
10 Day Avg. Volume1,312,069
30 Day Avg. Volume1,917,294
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Free Cash Flow GenerationA material FCF rebound in 2025 provides durable funding for debt reduction, R&D and launch investments, and the transformation program. If sustained, stronger cash conversion reduces refinancing risk and supports management's multi-year deleveraging and margin targets.
Rapidly Growing Specialty PortfolioHigh-growth, higher-margin specialty products are diversifying revenue away from volatile generics. Sustained adoption (AUSTEDO XR, UZEDY injection uptake, AJOVY traction) supports durable margin expansion and recurring cash flows as launches mature and payer access solidifies.
Transformation Program & Biosimilars PipelineA defined cost-savings program backed by early delivery increases operating leverage potential and complements a growing biosimilars build. Realized savings plus planned biosimilar launches provide structural support to margins and the firm's long-term free cash flow profile.
Bears Say
Elevated Leverage And Large Absolute DebtHigh absolute debt and past multi-year leverage weaken financial flexibility and increase sensitivity to cash-flow shocks. Although debt has trended down, sizeable outstanding obligations constrain capital allocation and mean deleveraging remains critical to lowering refinancing and covenant risks.
Generics Stagnation And Reliance On One‑offsA core generics business showing flat volumes and regional softness reduces topline resilience. Dependence on milestone revenues or one-time items to drive headline growth makes underlying cash and earnings less predictable over a multi-quarter horizon and challenges durable revenue diversification.
Material Product And Pipeline Execution RisksLosing Revlimid generics revenue and multiple binary clinical/regulatory milestones create tangible downside risk to forecasts. Replacing large legacy cash flows while depending on successful launches/readouts raises execution risk and could impair near-to-medium-term margin and deleveraging progress.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was 4865.00 and its highest was 11350.00 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is ₪121.70B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is May 13, 2026 which is in 84 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Jan 28, 2026. The company reported 297.3 earnings per share for the quarter, beating the consensus estimate of 203.4 by 93.9.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Overvalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 170.2.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of 297.3 in its last earnings report, beating expectations of 203.4. Following the earnings report the stock price went down -0.653%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
